WO2010042743A3 - Multiplexes chimères, compositions et procédés permettant de les utiliser - Google Patents
Multiplexes chimères, compositions et procédés permettant de les utiliser Download PDFInfo
- Publication number
- WO2010042743A3 WO2010042743A3 PCT/US2009/060040 US2009060040W WO2010042743A3 WO 2010042743 A3 WO2010042743 A3 WO 2010042743A3 US 2009060040 W US2009060040 W US 2009060040W WO 2010042743 A3 WO2010042743 A3 WO 2010042743A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- multiplexes
- chimeric
- compositions
- methods
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6919—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a ribbon or a tubule cochleate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10141—Use of virus, viral particle or viral elements as a vector
- C12N2730/10142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
L'invention concerne des multiplexes chimères thérapeutiques comprenant au moins deux capsides constituées, par exemple, d'une protéine centrale virale modifiée et d'un acide nucléique lié à la protéine centrale virale modifiée. L'acide nucléique peut être sensiblement homologue à une cible du gène spécifique. Dans certains modes de réalisation, l'acide nucléique lié à la protéine centrale virale modifiée est essentiellement non-immunogène.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10384308P | 2008-10-08 | 2008-10-08 | |
US61/103,843 | 2008-10-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010042743A2 WO2010042743A2 (fr) | 2010-04-15 |
WO2010042743A3 true WO2010042743A3 (fr) | 2010-10-28 |
Family
ID=42101213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/060040 WO2010042743A2 (fr) | 2008-10-08 | 2009-10-08 | Multiplexes chimères, compositions et procédés permettant de les utiliser |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010042743A2 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2747774A4 (fr) * | 2011-09-09 | 2015-02-11 | Biomed Realty L P | Procédés et compositions de régulation d'un assemblage de protéines virales |
GB201214746D0 (en) * | 2012-08-17 | 2012-10-03 | Cancer Rec Tech Ltd | Biomolecular complexes |
WO2020139843A1 (fr) * | 2018-12-28 | 2020-07-02 | The Board Of Trustee Of The Leland Stanford Junior University | Polypeptide noyau de l'hépatite b génétiquement modifié |
CN115461358A (zh) * | 2020-07-17 | 2022-12-09 | 养生堂有限公司 | 一种细胞穿膜肽及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020064533A1 (en) * | 1998-12-04 | 2002-05-30 | Kenneth Murray | HBV core antigen particles with multiple immunogenic components attached via peptide ligands |
US20030175290A1 (en) * | 2001-01-19 | 2003-09-18 | Cytos Biotechnology Ag | Molecular antigen array |
US20040059094A1 (en) * | 2002-07-18 | 2004-03-25 | Bachmann Martin F. | Hapten-carrier conjugates and uses thereof |
US20060216702A1 (en) * | 2002-05-17 | 2006-09-28 | Compans Richard W | Virus-like particles, methods of preparation, and immunogenic compositions |
-
2009
- 2009-10-08 WO PCT/US2009/060040 patent/WO2010042743A2/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020064533A1 (en) * | 1998-12-04 | 2002-05-30 | Kenneth Murray | HBV core antigen particles with multiple immunogenic components attached via peptide ligands |
US20030175290A1 (en) * | 2001-01-19 | 2003-09-18 | Cytos Biotechnology Ag | Molecular antigen array |
US20060216702A1 (en) * | 2002-05-17 | 2006-09-28 | Compans Richard W | Virus-like particles, methods of preparation, and immunogenic compositions |
US20040059094A1 (en) * | 2002-07-18 | 2004-03-25 | Bachmann Martin F. | Hapten-carrier conjugates and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2010042743A2 (fr) | 2010-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010042749A3 (fr) | Agents thérapeutiques chimères, compositions et procédés permettant de les utiliser | |
WO2010042755A3 (fr) | Agents thérapeutiques chimères, compositions et méthodes d'utilisation | |
WO2010042751A3 (fr) | Agents thérapeutiques chimères, compositions et procédés permettant de les utiliser | |
WO2012045082A3 (fr) | Synthèse d'acides nucléiques et méthodes d'utilisation associées | |
WO2012075040A3 (fr) | Arnm pour l'utilisation dans le traitement de maladies génétiques humaines | |
WO2012135805A3 (fr) | Administration et formulation d'acides nucléiques génétiquement modifiés | |
WO2008104890A3 (fr) | Compositions et procédés de production d'apolipoprotéine | |
WO2012019168A3 (fr) | Acides nucléiques modifiés et leurs procédés d'utilisation | |
WO2007130604A3 (fr) | ACTIVITÉ ANTI-TUMORALE D'UN ARNsi ONCOGÉNIQUE ADMINISTRÉ PAR UN ADÉNOVIRUS ONCOLYTIQUE | |
WO2007095316A3 (fr) | Compositions et procédés pour formulations à base d'oligonucléotides | |
EP2274442A4 (fr) | Séquences consensus de protéines du virus chikungunya, molécules d acide nucléique codant pour celles-ci, et compositions et procédés d utilisation de celles-ci | |
GB0922209D0 (en) | Proteins, nucleic acid molecules and compositions | |
WO2008028117A3 (fr) | Miméticorps glp-2, polypeptides, compositions, procédés et utilisations | |
WO2009149956A3 (fr) | Protéine de fusion et son utilisation | |
WO2007092704A8 (fr) | Gènes destinés à augmenter l'efficacité d'utilisation de l'azote dans des plantes cultivées | |
WO2015035162A3 (fr) | Variants de cas9 et leurs utilisations | |
WO2009099641A3 (fr) | Compositions protéiniques stabilisées | |
WO2010127304A3 (fr) | Procédés de séquençage | |
WO2009042186A3 (fr) | Edition génomique dans un dard-perche à l'aide de nucléases à doigt de zinc | |
WO2011072246A3 (fr) | Modification de l'adn induite par l'effecteur tal | |
WO2014106015A3 (fr) | Compositions protéiques à liaison multivalente | |
WO2008067423A3 (fr) | Procédé d'amélioration de l'introduction d'adn dans des cellules bactériennes | |
WO2012024526A3 (fr) | Conjugués, particules, compositions et procédés associés | |
WO2008011446A3 (fr) | Mimétiques de la glp-1 humaine, compositions, procédés et utilisations | |
WO2008121324A3 (fr) | Eléments de vecteurs d'expression recombinants (reve) destinés à augmenter l'expression de protéines recombinantes dans des cellules hôtes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09819899 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 16/06/2011) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09819899 Country of ref document: EP Kind code of ref document: A2 |